• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KINETIC CONCEPTS, INC. V.A.C.® DRAPE; OMP

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KINETIC CONCEPTS, INC. V.A.C.® DRAPE; OMP Back to Search Results
Model Number VACDSP
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Fungal Infection (2419); Skin Inflammation/ Irritation (4545)
Event Date 07/07/2023
Event Type  Injury  
Event Description
On 10-jul-2023 the following information was information was provided to kci by the patient: when v.A.C.® therapy was removed on (b)(6) 2023 there was irritation noted to the skin allegedly from the v.A.C.® granufoam¿ dressing coming in to contact with the patient's skin.She has been applying a powder to her skin twice a day and v.A.C.® therapy was placed on hold.On (b)(6) 2023, the following information was provided to kci by the nurse: v.A.C.® therapy was placed on hold allegedly due to an infection.On (b)(6) 2023, the following information was provided to kci by the nurse: the patient was hospitalized due to an infection.On (b)(6) 2023, the following information was provided to kci by the nurse: the patient was not hospitalized.V.A.C.® therapy was placed on hold on (b)(6) 2023 because the patient allegedly developed a yeast infection to the skin surrounding the wound.It could not be confirmed if the infection was due to the location of the patient's wound as it is in an abdominal fold or from the v.A.C.® drape.The patient was started on oral diflucan and topical nystatin powder and an alternative dressing was put in place.The infection has since improved and v.A.C.® therapy has been restarted.On (b)(6) 2023, the following information was provided to kci by the nurse: v.A.C.® therapy was placed on hold on (b)(6) 2023 for concerns of infection and the patient was evaluated by the physician on (b)(6) 2023.On (b)(6) 2023, a device history record review for the v.A.C.® granufoam¿ dressing lot number c11847v009 and associated v.A.C.® drape was completed.All end release testing of product and packaging met specifications.The v.A.C.® granufoam¿ dressing was not returned; therefore, a device evaluation could not be performed.
 
Manufacturer Narrative
Based on the information provided, it cannot be determined that the alleged yeast infection requiring medication is related to the v.A.C.® drape.All end release testing of product and packaging met specifications.A device evaluation could not be performed.Device labeling, available in print and online, states: warning: never leave a v.A.C.® dressing in place without active v.A.C.® therapy for more than two hours.If therapy is off for more than two hours, remove the old dressing and irrigate the wound.Either apply a new v.A.C.® dressing from an unopened sterile package and restart v.A.C.® therapy; or apply an alternate dressing, such as a wet to moist gauze, as approved during times of extreme need, by treating physician.Dressing changes wounds being treated with the v.A.C.® therapy system should be monitored on a regular basis.In a monitored, non-infected wound, v.A.C.® dressings should be changed every 48-72 hours, but no less than 3 times a week, with frequency adjusted by the clinician as appropriate.Infected wounds must be monitored often and very closely.For these wounds, dressings may need to be changed more often than 48-72 hours; the dressing changing intervals should be based on a continuing evaluation of the wound condition and the patient's clinical presentation, rather than a fixed schedule.Precautions the v.A.C.® therapy system will not be effective in addressing complications associated with the following: ischemia to the incision or incision area, untreated or inadequately treated infection, inadequate hemostasis of the incision, cellulitis of the incision area.Infected wounds: infected wounds should be monitored closely and may require more frequent dressing changes thanm noninfected wounds, dependent upon factors such as wound conditions, treatment goals.Refer to dressing application instructions (found in v.A.C.® dressing cartons) for details regarding dressing change frequency.As with any wound treatment, clinicians and patients / caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, worsening infection, or other complications.Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge or strong odor.Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/or fatal injury.Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/or orthostatic hypotension or erythroderma (a sunburn-like rash).If there are any signs of the onset of systemic infection or advancing infection at the wound site, contact the treating physician immediately to determine if v.A.C.® therapy should be discontinued.Disclaimer: this information is submitted pursuant to 21 cfr 803, in compliance with the medical device reporting requirement and should not be considered to be an admission that a kinetic concepts, inc.Product malfunctioned, is defective or has caused serious injury.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
V.A.C.® DRAPE
Type of Device
OMP
Manufacturer (Section D)
KINETIC CONCEPTS, INC.
san antonio TX 78249
Manufacturer Contact
steven jackson
6203 farinon drive
san antonio, TX 78249
2102556436
MDR Report Key17476587
MDR Text Key320583368
Report Number3009897021-2023-00057
Device Sequence Number1
Product Code OMP
UDI-Device Identifier00849554002098
UDI-Public01008495540020981725123110C11847V009
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K133276
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer,Health Professional
Reporter Occupation Nurse
Type of Report Initial
Report Date 08/07/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/07/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberVACDSP
Device Catalogue NumberM8275052
Device Lot NumberC11847V009
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/10/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/27/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age82 YR
Patient SexFemale
Patient Weight66 KG
-
-